mylaninclogo.jpg
08/06/2018 08:45:15
Fuente original

FDA approves Mylan and Biocon’s Fulphila, the first biosimilar to Neulasta

Mylan N.V. and Biocon Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved Mylan’s Fulphila (pegfilgrastim-jmbd), a biosimilar to Neulasta (pegfilgrastim), co-developed with Biocon.



Leer el artículo original completo